Curis at Cantor Global Healthcare: Emavusertib's Promise in Hematology

Curis Inc. (CRIS) outlined its strategic vision for emavusertib at the Cantor Global Healthcare Conference 2025, focusing on its multi-indication development. The company is advancing towards accelerated approval for emavusertib in PCNSL, with its pivotal single-arm study accepted by the FDA and EMA, targeting 45-60 patients for a 20-22% ORR despite enrollment challenges. Significantly, Curis plans to initiate a trial in CLL by year-end for patients with inadequate response to BTK inhibitors, aiming to achieve deeper responses and MRD negativity, representing a substantial market opportunity. An AML program update on combination therapy with azacitidine is also anticipated at ASH, collectively positioning Curis to address critical unmet needs in hematological malignancies.

Analysis

Curis Inc. is strategically focusing all its resources on a single asset, emavusertib, by pursuing a multi-indication development path in hematological malignancies. The most advanced program is in Primary Central Nervous System Lymphoma (PCNSL), where its Phase 1/2 trial has been designated as pivotal by both the FDA and EMA for accelerated approval. The company needs to enroll 45-60 patients and achieve an Overall Response Rate (ORR) of 20-22%; its current data from 34 patients shows a promising 27% ORR. However, the primary operational risk is the slow patient enrollment due to the disease's rarity, with a projected 12-18 month timeline to reach the target. The more significant long-term value driver is the expansion into Chronic Lymphocytic Leukemia (CLL), a market valued at over $7 billion. The strategy here is to combine emavusertib with BTK inhibitors in patients with inadequate responses, aiming to achieve deeper responses such as Minimal Residual Disease (MRD) negativity. This trial is set to begin by year-end, with a key interim readout for approximately 15 patients expected by mid-next year. A third program in Acute Myeloid Leukemia (AML), combining emavusertib with azacitidine, will have a status update at the upcoming ASH conference, serving as a near-term catalyst. Overall, Curis presents a catalyst-rich pipeline for a single drug, with a de-risked regulatory path in a small market (PCNSL) and a high-reward, but earlier-stage, opportunity in a large market (CLL).

Key Decisions for Investors

• Investors should closely monitor patient enrollment rates in the pivotal PCNSL trial, as the 12-18 month timeline is a critical execution risk for securing accelerated approval, despite the current ORR of 27% exceeding the regulatory bar.
• The interim data readout for the CLL trial, expected by mid-next year, represents a major potential inflection point; evidence of achieving MRD negativity in the first ~15 patients could significantly de-risk the asset's potential in this multi-billion dollar market.
• Pay close attention to the upcoming ASH conference for the status update on the emavusertib-azacitidine combination in AML, as this represents the next near-term data catalyst and provides another avenue for value creation.
• It is prudent to weigh the company's single-asset concentration risk against the significant upside from its multi-indication strategy, particularly the large but speculative CLL opportunity, which is currently a key driver of investor interest.